| Literature DB >> 26202935 |
J Etchin1,2, J Montero3, A Berezovskaya1, B T Le1, A Kentsis4, A L Christie1, A S Conway1, W C Chen5,6, C Reed1, M R Mansour1,7, C E L Ng1, S Adamia3, S J Rodig8, I A Galinsky3, R M Stone3, B Klebanov9, Y Landesman9, M Kauffman9, S Shacham9, A L Kung10, J C Y Wang5,6, A Letai3, A T Look1,2.
Abstract
Currently available combination chemotherapy for acute myeloid leukemia (AML) often fails to result in long-term remissions, emphasizing the need for novel therapeutic strategies. We reasoned that targeted inhibition of a prominent nuclear exporter, XPO1/CRM1, could eradicate self-renewing leukemia-initiating cells (LICs) whose survival depends on timely XPO1-mediated transport of specific protein and RNA cargoes. Using an immunosuppressed mouse model bearing primary patient-derived AML cells, we demonstrate that selinexor (KPT-330), an oral antagonist of XPO1 that is currently in clinical trials, has strong activity against primary AML cells while sparing normal stem and progenitor cells. Importantly, limiting dilution transplantation assays showed that this cytotoxic activity is not limited to the rapidly proliferating bulk population of leukemic cells but extends to the LICs, whose inherent drug resistance and unrestricted self-renewal capacity has been implicated in the difficulty of curing AML patients with conventional chemotherapy alone.Entities:
Mesh：
Substances：
Year: 2015 PMID： 26202935 PMCID： PMC4994896 DOI： 10.1038/leu.2015.194
Source DB: PubMed Journal: Leukemia ISSN： 0887-6924 Impact factor: 11.528